nct_id: NCT07063745
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2025-07-14'
study_start_date: null
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: Cisplatin'
  - drug_name: 'Drug: Carboplatin'
  - drug_name: 'Drug: BMS-986504'
  - drug_name: 'Drug: Nab-paclitaxel'
  - drug_name: 'Drug: Pemetrexed'
  - drug_name: 'Other: Placebo'
  - drug_name: 'Drug: Paclitaxel'
  - drug_name: 'Drug: Pembrolizumab'
long_title: A Randomized Phase 2/3 Study of BMS-986504 in Combination With Pembrolizumab
  and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line
  Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
last_updated: '2025-11-12'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE2
principal_investigator: NA
principal_investigator_institution: Bristol-Myers Squibb
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 590
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- Inclusion Criteria
- '* Participants must have Metastatic (Stage IV or recurrent) non-small cell lung
  cancer (NSCLC) (as defined by the American Joint Committee on Cancer, Ninth Edition)
  with no prior systemic anti-cancer therapy for metastatic disease.'
- '* Participants must have histologically confirmed diagnosis of NSCLC and homozygous
  methylthioadenosine phosphorylase (MTAP) deletion or MTAP loss.'
- '* Participants must have an Eastern Cooperative Oncology Group (ECOG) performance
  status of 0-1.'
- '* Participants must have at least 1 measurable lesion as per RECIST v1.1.'
- Exclude - Exclusion Criteria
- Exclude - * Nonsquamous participants must not have documented targetable oncogenic
  mutation or actionable genetic alterations (AGAs) for which there is a standard
  of care (SoC) available as first-line (1L) therapy.
- Exclude - * Participants must not have symptomatic brain metastases or spinal cord
  compression.
- 'Exclude - * Participants must not have any prior systemic therapy (chemotherapy,
  immunotherapy, targeted therapy, or biological therapy) for metastatic non-small
  cell lung cancer (mNSCLC). Note: One cycle of SoC treatment prior to randomization
  will be allowed for participants who require immediate treatment if clinically indicated.'
- Exclude - * Participants must not have any known or suspected impairment of gastrointestinal
  function that may prohibit the ability to absorb or swallow an oral medication without
  chewing or crushing.
- Exclude - * Other protocol-defined Inclusion/Exclusion criteria apply.
short_title: A Study to Compare the Combination of BMS-986504 With Pembrolizumab and
  Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic
  Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: Bristol-Myers Squibb
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: The purpose of this study is to compare the clinical benefit of the combination
  of BMS-986504 (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab
  and chemotherapy versus placebo plus pembrolizumab and chemotherapy in first-line
  metastatic non-small cell lung cancer participants with homozygous MTAP deletion
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: 'Arm A: BMS-986504 + Pembrolizumab + Chemotherapy'
      arm_internal_id: 0
      arm_description: 'Arm A: BMS-986504 + Pembrolizumab + Chemotherapy'
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: BMS-986504'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Pembrolizumab'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: Cisplatin'
        level_internal_id: 2
        level_suspended: N
      - level_code: '3'
        level_description: 'Drug: Carboplatin'
        level_internal_id: 3
        level_suspended: N
      - level_code: '4'
        level_description: 'Drug: Pemetrexed'
        level_internal_id: 4
        level_suspended: N
      - level_code: '5'
        level_description: 'Drug: Paclitaxel'
        level_internal_id: 5
        level_suspended: N
      - level_code: '6'
        level_description: 'Drug: Nab-paclitaxel'
        level_internal_id: 6
        level_suspended: N
    - arm_code: 'Arm B: BMS-986504 + Pembrolizumab + Chemotherapy'
      arm_internal_id: 1
      arm_description: 'Arm B: BMS-986504 + Pembrolizumab + Chemotherapy'
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: BMS-986504'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Pembrolizumab'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: Cisplatin'
        level_internal_id: 2
        level_suspended: N
      - level_code: '3'
        level_description: 'Drug: Carboplatin'
        level_internal_id: 3
        level_suspended: N
      - level_code: '4'
        level_description: 'Drug: Pemetrexed'
        level_internal_id: 4
        level_suspended: N
      - level_code: '5'
        level_description: 'Drug: Paclitaxel'
        level_internal_id: 5
        level_suspended: N
      - level_code: '6'
        level_description: 'Drug: Nab-paclitaxel'
        level_internal_id: 6
        level_suspended: N
    - arm_code: 'Arm C: Placebo + Pembrolizumab + Chemotherapy'
      arm_internal_id: 2
      arm_description: 'Arm C: Placebo + Pembrolizumab + Chemotherapy'
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Pembrolizumab'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Other: Placebo'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: Cisplatin'
        level_internal_id: 2
        level_suspended: N
      - level_code: '3'
        level_description: 'Drug: Carboplatin'
        level_internal_id: 3
        level_suspended: N
      - level_code: '4'
        level_description: 'Drug: Pemetrexed'
        level_internal_id: 4
        level_suspended: N
      - level_code: '5'
        level_description: 'Drug: Paclitaxel'
        level_internal_id: 5
        level_suspended: N
      - level_code: '6'
        level_description: 'Drug: Nab-paclitaxel'
        level_internal_id: 6
        level_suspended: N
    - arm_code: 'Arm D: Placebo + Pembrolizumab + Chemotherapy'
      arm_internal_id: 3
      arm_description: 'Arm D: Placebo + Pembrolizumab + Chemotherapy'
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Pembrolizumab'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Other: Placebo'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: Cisplatin'
        level_internal_id: 2
        level_suspended: N
      - level_code: '3'
        level_description: 'Drug: Carboplatin'
        level_internal_id: 3
        level_suspended: N
      - level_code: '4'
        level_description: 'Drug: Pemetrexed'
        level_internal_id: 4
        level_suspended: N
      - level_code: '5'
        level_description: 'Drug: Paclitaxel'
        level_internal_id: 5
        level_suspended: N
      - level_code: '6'
        level_description: 'Drug: Nab-paclitaxel'
        level_internal_id: 6
        level_suspended: N
    - arm_code: 'Arm E: BMS-986504 + Pembrolizumab + Chemotherapy'
      arm_internal_id: 4
      arm_description: 'Arm E: BMS-986504 + Pembrolizumab + Chemotherapy'
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: BMS-986504'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Pembrolizumab'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: Cisplatin'
        level_internal_id: 2
        level_suspended: N
      - level_code: '3'
        level_description: 'Drug: Carboplatin'
        level_internal_id: 3
        level_suspended: N
      - level_code: '4'
        level_description: 'Drug: Pemetrexed'
        level_internal_id: 4
        level_suspended: N
      - level_code: '5'
        level_description: 'Drug: Paclitaxel'
        level_internal_id: 5
        level_suspended: N
      - level_code: '6'
        level_description: 'Drug: Nab-paclitaxel'
        level_internal_id: 6
        level_suspended: N
    - arm_code: 'Arm F: Placebo + Pembrolizumab + Chemotherapy'
      arm_internal_id: 5
      arm_description: 'Arm F: Placebo + Pembrolizumab + Chemotherapy'
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Pembrolizumab'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Other: Placebo'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: Cisplatin'
        level_internal_id: 2
        level_suspended: N
      - level_code: '3'
        level_description: 'Drug: Carboplatin'
        level_internal_id: 3
        level_suspended: N
      - level_code: '4'
        level_description: 'Drug: Pemetrexed'
        level_internal_id: 4
        level_suspended: N
      - level_code: '5'
        level_description: 'Drug: Paclitaxel'
        level_internal_id: 5
        level_suspended: N
      - level_code: '6'
        level_description: 'Drug: Nab-paclitaxel'
        level_internal_id: 6
        level_suspended: N
    match:
    - clinical:
        age_numerical: '>=18'
        disease_status:
        - Metastatic
        - Recurrent
        oncotree_primary_diagnosis: Non-Small Cell Lung Cancer
